Characterization of pre- and post-treatment pathology after enzyme replacement therapy for Pompe disease (Q39773493)

14 September 2017

Characterization of pre- and post-treatment pathology after enzyme replacement therapy for Pompe disease (English)

1 reference

enzyme replacement therapy

14 September 2017

0 references

0 references

1

Beth L Thurberg

1 reference

14 September 2017

Colleen Lynch Maloney

2

1 reference

14 September 2017

Charles Vaccaro

3

1 reference

14 September 2017

Kendra Afonso

4

1 reference

14 September 2017

Anne Chun-Hui Tsai

5

1 reference

14 September 2017

Edward Bossen

6

1 reference

14 September 2017

Priya S Kishnani

7

1 reference

14 September 2017

Michael O'Callaghan

8

1 reference

14 September 2017

30 October 2006

1 reference

14 September 2017

Laboratory Investigation

1 reference

14 September 2017

86

1 reference

14 September 2017

12

1 reference

14 September 2017

1208-1220

1 reference

https://scigraph.springernature.com/pub.10.1038/labinvest.3700484

14 September 2017

0 references

cites work

The natural course of infantile Pompe's disease: 20 original cases compared with 133 cases from the literature

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700484

High-resolution light microscopy (HRLM) and digital analysis of Pompe disease pathology

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700484

Lysosomal dysfunction in muscle with special reference to glycogen storage disease type II.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700484

Type II glycogenosis. Biochemical and electron microscopic study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700484

Enzyme replacement therapy in the mouse model of Pompe disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700484

The number of nuclei in adult rat muscles with special reference to satellite cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700484

Recombinant human acid alpha-glucosidase enzyme therapy for infantile glycogen storage disease type II: results of a phase I/II clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700484

Long-term intravenous treatment of Pompe disease with recombinant human alpha-glucosidase from milk

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700484

Intractable fever and cortical neuronal glycogen storage in glycogenosis type 2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700484

A retrospective, multinational, multicenter study on the natural history of infantile-onset Pompe disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700484

7 January 2021

Infantile acid maltase deficiency. I. Muscle fiber destruction after lysosomal rupture

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700484

7 January 2021

Myogenic satellite cells: physiology to molecular biology

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700484

7 January 2021

Relationship between capillary angiogenesis, fiber type, and fiber size in chronic systemic hypoxia

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700484

7 January 2021

Capillary supply of the tibialis anterior muscle in young, healthy, and moderately active men and women

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700484

7 January 2021

Chinese hamster ovary cell-derived recombinant human acid alpha-glucosidase in infantile-onset Pompe disease

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700484

7 January 2021

Pompe's disease: an inborn lysosomal disorder with storage of glycogen. A study of brain and striated muscle.

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700484

7 January 2021

The pathology of type II skeletal muscle glycogenosis. A light and electron-microscopic study

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700484

7 January 2021

Juvenile acid maltase deficiency presenting as paravertebral pseudotumour

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700484

7 January 2021

The "muscular variant" of Pompe disease: clinical, biochemical and histologic characteristics

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700484

7 January 2021

Cellular localisation of transforming growth factor-beta 2 and -beta 3 (TGF-beta2, TGF-beta3) in damaged and regenerating skeletal muscles

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700484

7 January 2021

Blood flow to different rat skeletal muscle fiber type sections during isometric contractions in situ

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700484

7 January 2021

Dysfunction of endocytic and autophagic pathways in a lysosomal storage disease.

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700484

7 January 2021

The distribution of satellite cells and their relationship to specific fiber types in soleus and extensor digitorum longus muscles

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700484

7 January 2021

The conduction system in Pompe's disease

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700484

7 January 2021

Electrocardiographic response to enzyme replacement therapy for Pompe disease.

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700484

7 January 2021

Alpha-glucosidase deficiency and basilar artery aneurysm: report of a sibship

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700484

7 January 2021

Ambulatory electrocardiogram analysis in infants treated with recombinant human acid alpha-glucosidase enzyme replacement therapy for Pompe disease

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700484

7 January 2021

Nephrotic syndrome complicating alpha-glucosidase replacement therapy for Pompe disease

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700484

7 January 2021

Anaesthetic management of infants with glycogen storage disease type II: a physiological approach

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700484

7 January 2021

10.1038/LABINVEST.3700484

Identifiers

DOI

1 reference

Dimensions Publication ID

14 September 2017

0 references

1 reference